MMS, a data-focused clinical research organization (CRO), announced its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland.
This acquisition will add the company’s flagship product KerusCloud, a cloud-based statistical modeling and simulation platform to MMS’ data-driven approach towards efficient drug development.
With a history of strong organic growth, the acquisition of Exploristics positions MMS to enhance its global footprint and capabilities in advanced clinical trial design, innovative statistics, and data science. And building on its track record in regulatory and end-game submissions, this acquisition now solidifies MMS as the leader in biometrics and development strategy solutions for biotechnology and pharmaceutical sponsors of all sizes.
The acquisition of Exploristics by MMS aligns with the company’s focus on widening its data-focused solutions to enhance the ability to simulate, analyze, and optimize studies, reduce risk, and drive efficiencies. And by combining the two organizations’ strengths, MMS will now provide:
KEY QUOTES:
“We are proud to bring the Exploristics team into the #OneMMS family. When exploring acquisition opportunities to enhance our strategic capabilities as a leading data CRO, we sought organizations that would complement our existing regulatory approach and build a powerful combination of regulatory and statistical design expertise, combined with market-leading study simulation software. We found that in Exploristics, along with a like-minded culture.”
– Dr. Uma Sharma, CEO, MMS
“Exploristics joining MMS is an exceptional fit, and we look forward to delivering even greater value to our clients through optimized strategies that reduce the overall time and cost burden in drug development.”
– Chris Schoonmaker, Chief Operating Officer at MMS
“Joining MMS represents an exciting new chapter for Exploristics. Our ethos has always centered on openness, honesty, professionalism, flexibility, and creativity—qualities that I’ve experienced at MMS since day one of our discussions. I am confident that our employees, partners, and clients will benefit from this partnership as we amplify our impact and expand our global reach.”
– Aiden Flynn, Founder and CEO of Exploristics, now Senior Vice President, Head of Strategic Statistical Consulting at MMS
“Our presence in Europe has seen significant growth in recent years, and this acquisition adds to our vitality in the region. Our focus on data for better trial data execution, lower risk, stronger submissions, integration of Real-World Data (RWD) into clinical outputs and accelerated outcomes has never been stronger than it is today.”
– Ben Dudley, Chief Commercial Officer at MMS
